Insulet (PODD) Stock Forecast & Price Target

Compare

914 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PODD Analyst Ratings

Strong Buy

19 Buy

2 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Insulet

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PODD Stock 12 Month Forecast

Average Price Target

$345.83

▲(13.93% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $345.83 with a high forecast of $380.00 and a low forecast of $266.00. The average price target represents a 13.93% change from the last price of $303.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"196":"$196","381":"$381","242.25":"$242.3","288.5":"$288.5","334.75":"$334.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":345.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$345.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$266.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[196,242.25,288.5,334.75,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,284.91,292.2246153846154,299.5392307692308,306.8538461538462,314.16846153846154,321.48307692307696,328.79769230769233,336.1123076923077,343.4269230769231,350.7415384615385,358.05615384615385,365.37076923076927,372.68538461538463,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,284.91,289.59615384615387,294.2823076923077,298.96846153846155,303.6546153846154,308.34076923076924,313.0269230769231,317.7130769230769,322.39923076923077,327.0853846153846,331.77153846153846,336.4576923076923,341.14384615384614,{"y":345.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,284.91,283.4553846153846,282.00076923076927,280.54615384615386,279.0915384615385,277.6369230769231,276.1823076923077,274.72769230769234,273.2730769230769,271.8184615384615,270.36384615384617,268.90923076923076,267.4546153846154,{"y":266,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":197.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.77,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$380.00

Average Price Target$345.83

Lowest Price Target$266.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$345

Buy

13.66%

Upside

Reiterated

08/08/25

Insulet's strong financial performance and positive earnings call are the most significant factors driving the stock score. The company's robust revenue growth and improved profitability, along with raised guidance, reflect a strong market position. However, the high valuation and mixed technical indicators slightly temper the overall score.

Larry BiegelsenWells Fargo

Wells Fargo

$330→$350

Buy

15.30%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), CareDx (NASDAQ: CDNA) and Insulet (NASDAQ: PODD)

Robbie MarcusJ.P. Morgan

J.P. Morgan

$340

Buy

12.01%

Upside

Reiterated

08/07/25

Matthew TaylorJefferies

Jefferies

$360→$375

Buy

23.54%

Upside

Reiterated

08/07/25

Insulet price target raised to $375 from $360 at JefferiesInsulet price target raised to $375 from $360 at Jefferies

William PlovanicCanaccord Genuity

Canaccord Genuity

$331→$353

Buy

16.29%

Upside

Reiterated

08/07/25

Canaccord Genuity Sticks to Its Buy Rating for Insulet (PODD)

Josh JenningsTD Cowen

TD Cowen

$379

Buy

24.86%

Upside

Reiterated

08/07/25

Insulet's Strong Financial Performance and Optimistic Outlook Justify Buy Rating

Patrick WoodMorgan Stanley

Morgan Stanley

$335→$370

Buy

21.89%

Upside

Reiterated

08/07/25

Insulet's Strong Market Position and Growth Potential Justify Buy Rating with Increased Price Target

Brandon VazquezWilliam Blair

William Blair

―

Buy

―

Reiterated

08/07/25

Insulet's Strong Financial Performance and Growth Potential Justify Buy Rating

Shagun Singh ChadhaRBC Capital

RBC Capital

$330→$350

Buy

15.30%

Upside

Reiterated

08/07/25

Insulet (PODD) Gets a Buy from RBC Capital

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

07/21/25

We rate ABT, DXCM, PODD, and MDT Buy, and TNDM Sell/High Risk.

Mike KratkyLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/14/25

Marie ThibaultBTIG

BTIG

$330→$350

Buy

15.30%

Upside

Reiterated

07/14/25

Analysts' Top Healthcare Picks: Insulet (PODD), OrthoPediatrics (KIDS)

Travis SteedBank of America Securities

Bank of America Securities

$335

Buy

10.36%

Upside

Reiterated

07/07/25

Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD) and Arcutis Biotherapeutics (NASDAQ: ARQT)

Richard NewitterTruist Financial

Truist Financial

$365

Buy

20.24%

Upside

Initiated

06/16/25

Insulet initiated with a Buy at TruistInsulet initiated with a Buy at Truist

David RomanGoldman Sachs

Goldman Sachs

$380

Buy

25.19%

Upside

Initiated

05/30/25

Insulet (PODD) Receives a Buy from Goldman Sachs

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$345

Buy

13.66%

Upside

Reiterated

08/08/25

Larry BiegelsenWells Fargo

Wells Fargo

$330→$350

Buy

15.30%

Upside

Reiterated

08/08/25

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT), CareDx (NASDAQ: CDNA) and Insulet (NASDAQ: PODD)

Robbie MarcusJ.P. Morgan

J.P. Morgan

$340

Buy

12.01%

Upside

Reiterated

08/07/25

Matthew TaylorJefferies

Jefferies

$360→$375

Buy

23.54%

Upside

Reiterated

08/07/25

Insulet price target raised to $375 from $360 at JefferiesInsulet price target raised to $375 from $360 at Jefferies

William PlovanicCanaccord Genuity

Canaccord Genuity

$331→$353

Buy

16.29%

Upside

Reiterated

08/07/25

Canaccord Genuity Sticks to Its Buy Rating for Insulet (PODD)

Josh JenningsTD Cowen

TD Cowen

$379

Buy

24.86%

Upside

Reiterated

08/07/25

Insulet's Strong Financial Performance and Optimistic Outlook Justify Buy Rating

Patrick WoodMorgan Stanley

Morgan Stanley

$335→$370

Buy

21.89%

Upside

Reiterated

08/07/25

Insulet's Strong Market Position and Growth Potential Justify Buy Rating with Increased Price Target

Brandon VazquezWilliam Blair

William Blair

―

Buy

―

Reiterated

08/07/25

Insulet's Strong Financial Performance and Growth Potential Justify Buy Rating

Shagun Singh ChadhaRBC Capital

RBC Capital

$330→$350

Buy

15.30%

Upside

Reiterated

08/07/25

Insulet (PODD) Gets a Buy from RBC Capital

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

07/21/25

We rate ABT, DXCM, PODD, and MDT Buy, and TNDM Sell/High Risk.

Mike KratkyLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/14/25

Marie ThibaultBTIG

BTIG

$330→$350

Buy

15.30%

Upside

Reiterated

07/14/25

Analysts' Top Healthcare Picks: Insulet (PODD), OrthoPediatrics (KIDS)

Travis SteedBank of America Securities

Bank of America Securities

$335

Buy

10.36%

Upside

Reiterated

07/07/25

Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD) and Arcutis Biotherapeutics (NASDAQ: ARQT)

Richard NewitterTruist Financial

Truist Financial

$365

Buy

20.24%

Upside

Initiated

06/16/25

Insulet initiated with a Buy at TruistInsulet initiated with a Buy at Truist

David RomanGoldman Sachs

Goldman Sachs

$380

Buy

25.19%

Upside

Initiated

05/30/25

Insulet (PODD) Receives a Buy from Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insulet

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+4.18%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +4.18% per trade.

3 Months

xxx

Success Rate

15/16 ratings generated profit

Average Return

+14.16%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 93.75% of your transactions generating a profit, with an average return of +14.16% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

15/16 ratings generated profit

Average Return

+30.99%

reiterated a buy rating 2 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +30.99% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+68.30%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +68.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PODD Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PODD has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PODD average Analyst price target in the past 3 months is 345.83.

Each month's total comprises the sum of three months' worth of ratings.

PODD Financial Forecast

PODD Earnings Forecast

Next quarter’s earnings estimate for PODD is $1.14 with a range of $1.00 to $1.28. The previous quarter’s EPS was $1.17. PODD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year PODD has Preformed in-line its overall industry.

PODD Sales Forecast

Next quarter’s sales forecast for PODD is $674.27M with a range of $639.60M to $685.71M. The previous quarter’s sales results were $649.10M. PODD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year PODD has Preformed in-line its overall industry.

PODD Stock Forecast FAQ

What is PODD’s average 12-month price target, according to analysts?

Based on analyst ratings, Insulet’s 12-month average price target is 345.83.

What is PODD’s upside potential, based on the analysts’ average price target?

Insulet has 13.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PODD a Buy, Sell or Hold?

Insulet has a consensus rating of Strong Buy which is based on 19 buy ratings, 2 hold ratings and 0 sell ratings.

What is Insulet’s price target?

The average price target for Insulet is 345.83. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $380.00 ,the lowest forecast is $266.00. The average price target represents 13.93% Increase from the current price of $303.55.

What do analysts say about Insulet?

Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of PODD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Insulet (PODD) Stock Forecast & Price Target

PODD Analyst Ratings

PODD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insulet

PODD Analyst Recommendation Trends

PODD Financial Forecast

PODD Earnings Forecast

PODD Sales Forecast

PODD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts